Video
A Review of Data Supporting the Approval of Aducanumab for Alzheimer Disease
Findings from the 2 pivotal phase 3 trials had mixed results on cognitive benefit, although they found a positive reduction in amyloid plaque in patients' brains.
In an interview with Pharmacy Times, Pamela Spicer, senior analyst at Datamonitor with Informa Pharma Intelligence, reviewed the 2 pivotal phase 3 clinical trials supporting the FDA's recent approval of aducanumab. Notably, Spicer said 1 trial had a positive trend while the second trial had a negative trend, which resulted in the early cessation of both trials.
The findings had mixed results on cognitive benefit, although they found a positive reduction in amyloid plaque in patients' brains. Based on this, officials with the FDA approved the drug, Spicer said.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
